MedTrace Logo

A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model

NCT00731250 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2017-07-13

No results posted yet for this study

Summary

This study is designed to look at the affect of SB-705498 on rhinitis symptoms, as induced by capsaicin challenge

Conditions

  • Rhinitis

Interventions

DRUG

SB-705498

Subjects will be administered a single dose of 400 mg SB-705498

DRUG

Placebo

Subjects will be administered SB-705498 matching placebo tablets

OTHER

Caspaicin

Subjects will be challenged with 0.5 µg, 5.0 µg and 50 µg intranasal dose

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-22
Primary Completion
2009-03-01
Completion
2009-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00731250 on ClinicalTrials.gov